EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
Authors:
Open Access
- 1 October 2015
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 3017-3020
Abstract
The purpose of this study was to investigate the correlation between EGFR-mutation status and treatment efficacy for advanced lung adenocarcinoma patients. A total of 47 patients receiving erlotinib as first-line therapy were divided into two groups: the EGFR gene mutation group included 19 patients with known EGFR-sensitive mutations, and the EGFR-mutation status-unknown group comprised 28 patients with unknown EGFR-mutation status. Both objective response rate and disease-control rate were significantly higher in the EGFR-mutation group compared with the EGFR-unknown group (42.1% vs 14.2%, P=0.032; 94.7% vs 57.1%, P=0.005). Age, sex, smoking history, stage of disease, and tissue-sample source were not significantly correlated with the distributions of mutation status. In conclusion, it is important for advanced lung adenocarcinoma patients to undergo gene analysis before being assigned a molecularly targeted drug as first-line treatment.Keywords
This publication has 17 references indexed in Scilit:
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014
- Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 TrialJournal of Clinical Oncology, 2012
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the LungJournal of Clinical Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Lung CancerNew England Journal of Medicine, 2008
- High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in TaiwanClinical Cancer Research, 2004